HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis Trial

Liegler, Teri; Abdel-Mohsen, Mohamed; Bentley, L. Gordon; Atchison, Robert; Schmidt, Timothy; Javier, Jacqueline; Mehrotra, Megha; Eden, Christopher; Glidden, David V.; McMahan, Vanessa; Anderson, Peter L.; Li, Peilin; Wong, Joseph K.; Buchbinder, Susan; Guanira, Juan V.; Grant, Robert M.
October 2014
Journal of Infectious Diseases;Oct2014, Vol. 210 Issue 8, p1217
Academic Journal
Background. The iPrEx study demonstrated that combination oral emtricitabine and tenofovir disoproxil fumarate (FTC/TDF) as preexposure prophylaxis (PrEP) protects against HIV acquisition in men who have sex with men and transgender women. Selection for drug resistance could offset PrEP benefits.Methods. Phenotypic and genotypic clinical resistance assays characterized major drug resistant mutations. Minor variants with FTC/TDF mutations K65R, K70E, M184V/I were measured using 454 deep sequencing and a novel allele-specific polymerase chain reaction (AS-PCR) diagnostic tolerant to sequence heterogeneity.Results. Control of primer-binding site heterogeneity resulted in improved accuracy of minor variant measurements by AS-PCR. Of the 48 on-study infections randomized to FTC/TDF, none showed FTC/TDF mutations by clinical assays despite detectable drug levels in 8 participants. Two randomized to FTC/TDF had minor variant M184I detected at 0.53% by AS-PCR or 0.75% by deep sequencing, only 1 of which had low but detectable drug levels. Among those with acute infection at randomization to FTC/TDF, M184V or I mutations that were predominant at seroconversion waned to background levels within 24 weeks after discontinuing drug.Conclusions. Drug resistance was rare in iPrEx on-study FTC/TDF-randomized seroconverters, and only as low-frequency minor variants. FTC resistance among those initiating PrEP with acute infection waned rapidly after drug discontinuation.Clinical Trials Registration. NCT00458393.


Related Articles

  • No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV Preexposure Prophylaxis. Marcus, Julia L.; Glidden, David V.; Mayer, Kenneth H.; Liu, Albert Y.; Buchbinder, Susan P.; Amico, K. Rivet; McMahan, Vanessa; Kallas, Esper Georges; Montoya-Herrera, Orlando; Pilotto, Jose; Grant, Robert M. // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1 

    Objective: Preexposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) reduced HIV acquisition in the iPrEx trial among men who have sex with men and transgender women. Self-reported sexual risk behavior decreased overall, but may be affected by reporting bias. We...

  • Single-Tablet Emtricitabine-Rilpivirine- Tenofovir as HIV Postexposure Prophylaxis in Men Who Have Sex With Men. Foster, Rosalind; McAllister, John; Read, Tim R.; Pierce, Anna B.; Richardson, Robyn; McNulty, Anna; Carr, Andrew // Clinical Infectious Diseases;10/15/2015, Vol. 61 Issue 8, p1336 

    Background: Completion rates for human immunodeficiency virus (HIV) postexposure prophylaxis (PEP) are low. We investigated the adherence and safety of coformulated emtricitabine (FTC), rilpivirine (RPV), and tenofovir disoproxil fumarate (TDF) as a 3-drug, single-tablet regimen for PEP in men...

  • No New HIV Infections With Increasing Use of HIV Preexposure Prophylaxis in a Clinical Practice Setting. Volk, Jonathan E.; Marcus, Julia L.; Phengrasamy, Tony; Blechinger, Derek; Nguyen, Dong Phuong; Follansbee, Stephen; Hare, C. Bradley // Clinical Infectious Diseases;11/15/2015, Vol. 61 Issue 10, p1601 

    Referrals for and initiation of preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection increased dramatically in a large clinical practice setting since 2012. Despite high rates of sexually transmitted infections among PrEP users and reported decreases in condom use in a...

  • HIV pre-exposure prophylaxis and treatment as prevention: a review of awareness and acceptability among men who have sex with men in the Asia-Pacific region and the Americas. Holt, Martin // Sexual Health (14485028);2014, Vol. 11 Issue 2, p166 

    This review assesses acceptability research for HIV pre-exposure prophylaxis (PrEP) and treatment as prevention (TasP) among men who have sex with men (MSM) in the Asia-Pacific region and the Americas, evaluating awareness and attitudes. There has been limited research on the acceptability of...

  • ART-naive MSM source of transmitted drug-resistant HIV. Oldt, Amanda; Shafer, Emily; Volansky, Rob // Infectious Disease News;Nov2013, Vol. 26 Issue 11, p19 

    The article discusses research being done on the sources of transmitted drug-resistant HIV among men who have sex with men, which references a study by S. Drescher published in a 2013 issue of "Clinical Infectious Diseases."

  • Evolutionary History of HIV-1 Subtype B and CRF01_AE Transmission Clusters among Men Who Have Sex with Men (MSM) in Kuala Lumpur, Malaysia. Ng, Kim Tien; Ong, Lai Yee; Lim, Sin How; Takebe, Yutaka; Kamarulzaman, Adeeba; Tee, Kok Keng // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    HIV-1 epidemics among men who have sex with men (MSM) continue to expand in developed and developing countries. Although HIV infection in MSM is amongst the highest of the key affected populations in many countries in Southeast Asia, comprehensive molecular epidemiological study of HIV-1 among...

  • Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis. Havens, Peter L.; Stephensen, Charles B.; Van Loan, Marta D.; Schuster, Gertrud U.; Woodhouse, Leslie R.; Flynn, Patricia M.; Gordon, Catherine M.; Pan, Cynthia G.; Rutledge, Brandy; Nancy Liu; Wilson, Craig M.; Hazra, Rohan; Hosek, Sybil G.; Anderson, Peter L.; Seifert, Sharon M.; Kapogiannis, Bill G.; Mulligan, Kathleen // Clinical Infectious Diseases;2/1/2017, Vol. 64 Issue 3, p317 

    Background. We aimed to define the relative importance of renal and endocrine changes in tenofovir disoproxil fumarate (TDF)-related bone toxicity. Methods. In a study of daily TDF/emtricitabine (FTC) preexposure prophylaxis (PrEP) in human immunodeficiency virus (HIV)-uninfected young men who...

  • Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. Thigpen, Michael C.; Kebaabetswe, Poloko M.; Paxton, Lynn A.; Smith, Dawn K.; Rose, Charles E.; Segolodi, Tebogo M.; Henderson, Faith L.; Pathak, Sonal R.; Soud, Fatma A.; Chillag, Kata L.; Mutanhaurwa, Rodreck; Chirwa, Lovemore Ian; Kasonde, Michael; Abebe, Daniel; Buliva, Evans; Gvetadze, Roman J.; Johnson, Sandra; Sukalac, Thom; Thomas, Vasavi T.; Hart, Clyde // New England Journal of Medicine;8/2/2012, Vol. 367 Issue 5, p423 

    Background: Preexposure prophylaxis with antiretroviral agents has been shown to reduce the transmission of human immunodeficiency virus (HIV) among men who have sex with men; however, the efficacy among heterosexuals is uncertain. Methods: We randomly assigned HIV-seronegative men and women to...

  • Epidemiological overview: MSM and transgender women in Asia and the Pacific. Beyrer, Chris // HIV Australia;Nov2013, Vol. 11 Issue 4, p6 

    The article presents an overview of the epidemiology of HIV on men who have sex with men (MSM) and transgender women in Asia and the Pacific. It explores the prevalence of HIV in the region in 2013, highlighting the high HIV incidence and prevalence among MSM and transgender women. The impact of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics